Sensus Healthcare Granted U.S. Patent for Three-Dimensional Beam Forming X-Ray Source
February 23 2021 - 8:00AM
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical
device company specializing in highly effective, non-invasive,
minimally-invasive and cost-effective treatments for oncological
and non-oncological conditions, today announced that the U.S.
Patent and Trademark Office (USPTO) has granted the Company Patent
No. 10,607,802 B2, titled “Three-Dimensional Beam Forming X-Ray
Source.” This patent, which contains 31 separate claims, describes
the method of beam splitting and sculpting found in the Sculptura™
System, the Company’s Anisotropic Radiation Therapy with Beam
Sculpting™ capabilities and Robotic Respiratory Tracking for up to
17 different indications.
“We are delighted that the USPTO has recognized
our unique technology with the granting of this important patent,
the first of its kind in the world,” said Joe Sardano, chairman and
chief executive officer of Sensus Healthcare. “This new patent
opens doors for the delivery of radiation to treat solid tumors of
all types. In addition, there may be use for licensing this
technology for devices other than Sculptura. This is the
fifth U.S. patent granted Sensus since the start of 2020, and I
congratulate our talented engineers who have developed this
game-changing approach to the use of radiation to treat
cancer.”
U.S. Patent 10,607,802 B2 concerns a method and
system for controlling an electron beam, which involves generating
an electron beam and positioning a target element in its path. The
patent also covers the X-ray source, comprised of an electron beam
generator (EBG) configured to generate an electron beam. The EGB
control system selectively controls at least one of a beam pattern
and a direction of the X-ray beam by selectively varying a location
where the electron beam intersects the target element. The Sensus
Healthcare technology, currently embedded in the Sculptura System,
differs from IORT in its ability to control the radiation beam, and
has a longer useful operating life.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device
company specializing in highly effective, non-invasive,
minimally-invasive and cost-effective treatments for both
oncological and non-oncological conditions. The Sculptura™
modulated robotic brachytherapy radiation oncology system provides
targeted directional anisotropic radiation therapy (ART) and
brachytherapy utilizing our proprietary, state-of-the-art 3D Beam
Sculpting™ to treat patients undergoing cancer treatment during
surgery, or at the tumor site, fast and efficiently. Sensus also
offers its proprietary low-energy x-ray technology known as
superficial radiation therapy (SRT), which is the culmination of
more than a decade of research and development, to treat
non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™
and SRT-100 Vision™ systems. With its portfolio of innovative
medical device products, Sensus provides revolutionary treatment
options to enhance the quality of life of patients around the
world.
For more information, please visit
www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are,
or may be deemed, ''forward-looking statements.'' In some cases
these forward-looking statements can be identified by the use of
forward-looking terminology including "believes," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could,"
"might," "will," "should," "approximately," "potential" or, in each
case, their negative or other variations thereon or comparable
terminology, although not all forward-looking statements contain
these words.
By their nature, forward-looking statements
involve risks and uncertainties because they relate to events,
competitive dynamics and healthcare, regulatory and scientific
developments, and depend on the economic circumstances that may or
may not occur in the future or may occur on longer or shorter
timelines than anticipated. Although we believe that we have a
reasonable basis for each forward-looking statement contained in
this press release, we caution you that forward-looking statements
are not guarantees of future performance and that our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate may differ
materially from the forward looking statements contained in this
press release, as a result of, among other factors: the
continuation and severity of the COVID-19 pandemic, including its
impact on sales and marketing; our ability to achieve and sustain
profitability; market acceptance of our product lines; our ability
to successfully commercialize our products; our ability to compete
effectively in selling our products and services, including
responding to technological change and cost containment efforts of
our customers; our need and ability to obtain additional financing
in the future; our ability to expand, manage and maintain our
direct sales and marketing organizations; our ability to obtain and
maintain intellectual property of sufficient scope to adequately
protect our products, and our ability to avoid infringing or
otherwise violating the intellectual property rights of third
parties; the willingness of healthcare providers to purchase our
products if coverage, reimbursement and pricing from third party
payors for procedures using our products declines; the level and
availability of government and third party payor reimbursement for
clinical procedures using our products; our ability to effectively
manage our anticipated growth, including hiring and retaining
qualified personnel; the regulatory requirements applicable to us
and our competitors; our ability to manufacture our products to
meet demand; our current reliance on third party manufacturers and
sole- or single-source suppliers, as well as our ability to
successfully transition manufacturing of our products in-house; our
ability to reduce the per unit manufacturing costs; our ability to
efficiently manage our manufacturing processes; the regulatory and
legal risks, and certain operating risks, that our international
operations subject us to; the fact that product quality issues or
product defects may harm our business; the accuracy of our
financial statements and accounting estimates, including allowances
for accounts receivable and inventory obsolescence; any product
liability claims; new legislation, administrative rules, or
executive orders, including those that impact taxes and
international trade regulation; concentration of our customers in
the U.S. and China, including the concentration of sales to one
particular customer in the U.S.; and other risks described from
time to time in Sensus Healthcare's filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
In addition, even if our results of operations,
financial condition and liquidity, and the development of the
industry in which we operate are consistent with the
forward-looking statements contained in this press release, they
may not be predictive of results or developments in future periods.
Any forward-looking statements that we make in this press release
speak only as of the date of such statement, and we undertake no
obligation to update such statements to reflect events or
circumstances after the date of this press release. You should read
carefully our "Cautionary Note Regarding Forward-Looking
Information" and the factors described in the "Risk Factors"
section of our periodic reports filed with the Securities and
Exchange Commission to better understand the risks and
uncertainties inherent in our business.
Contact: LHA Investor
RelationsKim Sutton Golodetz212-838-3777kgolodetz@lhai.com
# # #
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From Apr 2024 to May 2024
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From May 2023 to May 2024